Suzhou Medical College Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2011
NCT01668615
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

First Affiliated Hospital of Suzhou Medical College

Active Ingredients

Drugs in Phase 2 Trials (1)

niraparib (zejula) (1 trial)

Drugs in Phase 1 Trials (2)

donafenib (1 trial)

hsk7653 (1 trial)

Drugs in Other Trials (2)

sirolimus (rapamune) (1 trial)

tretinoin (Retin-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5